ESR1 and breast carcinoma: Upon estrogen-stimulation, eribulin showed potent antitumor effects on estrogen receptor positive (ER+) breast cancer cells, whereas the combined treatment of eribulin with an antiestrogen resulted in a weakly-additive antitumor effect.